Dr. Vassilios Aslanis is Vice President, Clinical Pharmacology of Sudo Biosciences.  Prior to joining Sudo, Vassilios held senior leadership roles at Galecto Biotech, Ipsen, Novartis, and Pierre Fabre, where he led global clinical pharmacology and pharmacometrics strategies across multiple stages of development. His experience spans a broad range of therapeutic areas, including oncology, fibrotic diseases, rare diseases, and neuroscience.

Vassilios holds a PharmD and an MSc in Pharmacokinetics and Pharmacometrics and is currently completing a Ph.D. in Translational Drug Development. He is actively involved in academic teaching, scientific publishing, and professional societies.